On November 25, 2025 GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, reported that it has received a milestone payment under its collaboration agreement with Mitsubishi Tanabe Pharma Corporation (MTPC). GV20 and MTPC entered into this collaboration in early 2025 to leverage GV20’s antibodies, which are specifically directed against novel tumor antigen targets discovered through GV20’s proprietary STEAD AI platform, to generate potentially first-in-class antibody-drug conjugates (ADCs).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to reach this important milestone in our partnership with MTPC," said Ying Gong, Ph.D., Chief Business Officer of GV20. "This progress reflects our shared commitment to rapidly advancing innovative ADC therapies for patients with cancer. We look forward to continuing this positive momentum."

Under the terms of the agreement, GV20 received an upfront payment and is eligible for milestone payments. MTPC received an exclusive right to negotiate a license to these antibodies during the collaboration term.

(Press release, GV20 Therapeutics, NOV 25, 2025, View Source [SID1234660953])

On November 25, 2025 Immorta Bio Inc., a scientific longevity company pioneering therapies focusing on Treating Diseases of Aging and Treating Aging as Disease, reported the publication of its international patent application PCT/WO2025184665[1], entitled "Senescence Vaccine."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The application describes Immorta Bio’s proprietary approach to stimulating the immune system to selectively eliminate senescent cells: the dysfunctional "old cells" that drive aging, inflammation, organ failure, and support tumor growth. Removing these harmful cells results in a broad anti-aging effect throughout the body while simultaneously inhibiting cancer progression, addressing two major root causes of age-related decline:

accumulation of damage, and
loss of regenerative capacity.

At the center of the patent is SenoVax, Immorta Bio’s first-in-class senolytic immunotherapy, which has demonstrated potent reduction of lung, breast, brain, skin, and pancreatic cancers in established in vivo models[2]. SenoVax is also the subject of FDA submission of IND #30745 for advanced lung cancer[3].

"SenoVax is a true first-in-class immunotherapy," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, and inventor on 26 of the company’s patent applications. "By killing senescent cells, we reduce aging biology itself while simultaneously disrupting the tumor-supportive microenvironment required for cancer survival."

Immorta Bio’s broader longevity strategy combines SenoVax with StemCellRevivify, the company’s platform for introducing young, organ-specific progenitor and mesenchymal stem cells to restore regenerative capacity. Together, the two platforms target the two fundamental drivers of aging — impaired clearance of damaged cells and loss of tissue regeneration.

"Cancer is the most prevalent disease of aging, and SenoVax allows us to attack both aging biology and tumor biology at the same time," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio. "Our clinical goal is to first establish safety and efficacy in advanced cancer patients and then expand into age-related conditions and ultimately into treating aging itself."

Immorta Bio’s preclinical work shows compelling evidence across:

multiple cancer models
aging and frailty models
organ-failure models
>100% extension of lifespan and improvement in healthspan
These results, along with the publication of this PCT application, strengthen Immorta Bio’s position as the only company developing a dual-platform solution to aging that also treats its most lethal diseases.

(Press release, Immorta Bio, NOV 25, 2025, View Source [SID1234660952])

On November 25, 2025 Innova Therapeutics, a biopharmaceutical company, reported that it has completed the acquisition of Enci Therapeutics. The acquisition includes Enci Therapeutics’ main cancer therapeutic program, IVT-8086. The specific terms of the agreement and financial details regarding the acquisition between Innova Therapeutics and Enci Therapeutics have not been disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IVT-8086 is a first-in-class, humanized monoclonal antibody (mAb) developed as a cancer therapeutic that targets and antagonizes the Secreted Frizzled-Related Protein 2 (SFRP2) pathway. SFRP2, secreted by tumor and endothelial cells, activates the non-canonical Wnt/Calcium (Ca2+) signaling cascade, a pathway involved in angiogenesis, cell survival, cell growth and proliferation, cell migration and invasion, oncogenesis, and metastasis in cancer. By blocking SFRP2 in preclinical models, IVT-8086 induces multiple antitumor effects, including potent reduction in tumor burden in primary and metastatic tumors, reduced expression of CD38 and PD-1 in tumor-infiltrating lymphocytes (TILs), inhibition of angiogenesis, and increased interferon gamma (IFNγ) in tumor-associated macrophages (TAMs) resulting in macrophage repolarization and subsequent increase in the M1/M2 ratio.

The SFRP2 pathway is highly expressed across numerous solid and hematologic malignancies, positioning IVT-8086 as a potential therapy both as monotherapy and combination with immune checkpoint inhibitors (ICIs) for multiple cancer types. Extensive internal and external validation confirms SFRP2 as a critical molecular target, with expression levels strongly correlating with patient outcomes. In parallel, a diagnostic assay is in development to serve as a potential marker for early cancer detection, a prognostic tool for assessing therapeutic benefit, and an indicator for cancer recurrence risk.

"The acquisition of Enci Therapeutics and IVT-8086 marks a pivotal step for Innova Therapeutics in our commitment to pioneering novel cancer therapies," said Robert Ryan, Ph.D., Chief Executive Officer of Innova Therapeutics. "IVT-8086’s unique mechanism of action, antagonizing SFRP2 and selectively blocking the non-canonical Wnt/Ca2+ pathway, holds substantial promise for addressing a spectrum of solid tumors, including pediatric osteosarcoma, sarcomas, breast cancer and pancreatic cancer."

"This cancer treatment platform has the highest potential in my view to change the paradigm of treatment of patients with many types of solid and hematological cancers, resulting in long term survival," said Dr. Ryan who has worked for more than 30 years in the pharmaceutical industry developing cancer therapies. "Given the extensive global patent protection (including composition of matter) through 2042 and beyond, the commercial value of this platform is high, both as monotherapy and in combination."

"This strategic acquisition of Enci Therapeutics by Innova Therapeutics, centered around IVT-8086, a monoclonal antibody targeting SFRP2, underscores our dedication to advancing treatment paradigms for refractory cancers," said Nancy Klauber-DeMore M.D., Co-founder of Enci Therapeutics. "The potential of IVT-8086 to disrupt angiogenesis, tumor cell growth and survival, immune system function, and metastasis represents a significant opportunity to improve outcomes for patients facing these challenging diseases."

About IVT-8086

IVT-8086 is a first-in-class cancer therapeutic, developed as a humanized monoclonal antibody (mAb) designed to antagonize Secreted Frizzled Related Protein 2 (SFRP2). SFRP2 is a protein expressed at high levels in many solid and hematological malignancies, and its expression is correlated with patient outcomes including overall survival making it an important therapeutic target. IVT-8086 as an SFRP2 antagonist, selectively blocks the non-canonical Wnt/Ca2+ signaling pathway.

(Press release, Innova Therapeutics, NOV 25, 2025, View Source [SID1234660951])

On November 25, 2025 Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, reported an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered in Buenos Aires, Argentina, with decades of experience in biosimilar development and commercialization, for the commercialization of Tuznue (trastuzumab) across Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tuznue is a biosimilar to Herceptin (trastuzumab), approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received European Commission (EC) marketing authorization for Tuznue in September 2024. This approval marks a major milestone for the company’s biosimilar portfolio, signaling progress in expanding access to cost-effective treatments across key global markets.

Under the agreement, Biosidus secures exclusive rights to market and distribute Tuznue in Argentina, Mexico, Bolivia, and Paraguay, leveraging its extensive commercial network and deep expertise in biosimilar adoption. Prestige Biopharma will be responsible for the production and supply of the drug substance through its EU-GMP-certified, high-tech facility equipped with advanced single-use technology. Biosidus will manufacture the drug product at its facility in Buenos Aires, Argentina, from which it will supply the product to the local market, and export the product to the markets of Mexico, Paraguay and Bolivia.

Lisa S. Park, CEO of Prestige BioPharma, commented: "We are pleased to announce our strategic partnership with Biosidus for Argentina and other key markets in Latin America. With its proven track record and deep regional expertise, Biosidus represents an ideal partner for the successful manufacturing and commercialization of our lead biosimilar. We are confident that this collaboration will further enhance the global value and reach of our biosimilar portfolio."

Mariano Elizalde, CEO of Biosidus, said: "We are proud to partner with Prestige Biopharma to introduce Tuznue in selected markets across Latin America. This agreement strengthens our Biosimilars portfolio and our commitment to expand access to biotechnological medicines in Latin America. Together with Prestige Biopharma, we are confident in offering patients and healthcare professionals a quality and affordable therapeutic option".

About Tuznue
Tuznue is a biosimilar of Herceptin (trastuzumab), developed to offer a more cost-effective therapeutic alternative for patients. It maintains comparable efficacy and safety profiles to the original branded medication. Tuznue is indicated for the treatment of patients with HER2-positive metastatic breast cancer (MBC), HER2-positive early breast cancer (EBC), and HER2-positive metastatic gastric cancer (MGC).

(Press release, Prestige BioPharma, NOV 25, 2025, View Source [SID1234660950])

On November 25, 2025 Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), reported it will exhibit at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, taking place December 6–9, 2025, in Orlando, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Citius Oncology team will be located at Booth #265 in the ASH (Free ASH Whitepaper) Exhibit Hall to discuss LYMPHIR (denileukin diftitox-cxdl), its novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Company representatives will be available throughout the meeting to engage with physicians, researchers and the broader CTCL and oncology communities.

"We look forward to showcasing LYMPHIR at ASH (Free ASH Whitepaper) 2025 and engaging directly with the oncology community," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharma. "This event offers a great platform to meet with CTCL stakeholders to discuss how LYMPHIR’s clinical profile may offer an important treatment option for patients with cutaneous T-cell lymphoma."

The ASH (Free ASH Whitepaper) Annual Meeting is the world’s premier event in malignant and non-malignant hematology, bringing together more than 25,000 clinicians, scientists, and industry leaders from around the globe. The meeting features cutting-edge research, expert education sessions, and an expansive exhibit hall showcasing the latest advances in hematologic innovation.

About LYMPHIR (denileukin diftitox-cxdl)

LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.

In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA in August 2024.

About Cutaneous T-cell Lymphoma

Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the immune system, become cancerous and develop into skin lesions, leading to a decrease in the quality of life of patients with this disease due to severe pain and pruritus. Mycosis Fungoides (MF) and Sézary Syndrome (SS) comprise the majority of CTCL cases. Depending on the type of CTCL, the disease may progress slowly and can take anywhere from several years to upwards of ten to potentially reach tumor stage. However, once the disease reaches this stage, the cancer is highly malignant and can spread to the lymph nodes and internal organs, resulting in a poor prognosis. Given the duration of the disease, patients typically cycle through multiple agents to control disease progression. CTCL affects men twice as often as women and is typically first diagnosed in patients between the ages of 50 and 60 years of age. Other than allogeneic stem cell transplantation, for which only a small fraction of patients qualify, there is currently no curative therapy for advanced CTCL.

(Press release, Citius Oncology, NOV 25, 2025, View Source [SID1234660949])